143 pharmaceutical companies disclosed half-yearly reports, more than half of the results of the pre-performance.

Pharmaceutical Network Industry Dynamics In the year under the influence of the epidemic all walks of life are affected by different degrees of impact on the pharmaceutical industry is no exceptionAccording to data show that as of the month, a total of pharmaceutical companies disclosed the first half of the results of which the above-performing pre-profit profit of enterprises as high as 100 million yuanMeirui Medical, Xinhecheng, medicine Mingkang, Changchun high-tech, Kyushu Tong and other householdnet profit of more than 100 million yuan;Domestic pharmaceutical companies disclosed half-yearly results of the first half of the pre-expected "medical equipment one brother" Meirui Medical ranked as high as 100 million yuan in net profit; But there is a pre-increase there is a pre-fall performance report does not rise and fall the enterprise also many expected losses fell more than some homeAmong them, the international medical change is expected to be greaterIn addition to the United States year health, ji medicine holding, Tiansheng, Asia-Pacific pharmaceutical and other enterprises also showed the first lossThe net profit loss of The New Year Health, Junshi Bio is more than 100 million yuan, Tiansheng, International Medicine, Yihua Health and other households fell by more than a thousand yammachines and even received the Shenzhen Stock Exchange on the company's stock termination listing decisionFrom the above data, compared with the previous pharmaceutical industry in the first half of the report card is not ideal for the major pharmaceutical companies have entered the overall transition periodAccording to incomplete statistics, there are now domestic pharmaceutical company executives announced their resignationsIn fact, the results of this performance target of the results of the unexpected and frequent personnel changes are directly related to the national health care policy, especially the volume of procurementThe first two rounds of national drug collection has landed in the country a variety involving hundreds of pharmaceutical companies prices close to waist cut and the third batch of national drug collection and in the intensive preparation, whether the selection or not the selection for pharmaceutical enterprises will be in the industry form under the change simply ushered in great changesOverall, most pharmaceutical listed companies in the first half of the report card compared to previous years is not so ideal, but the pharmaceutical sector still become one of the direction of the positive fundsIndustry experts believe that the safe haven properties of medicine still existAccording to statistics as of the end of the month, the pharmaceutical biological index rose to the rank of industryFrom a market value point of view compared with the end of last year, the pharmaceutical and biological sector overall market value increase of trillion increase in the industry's topIn the future, the innovation ability of Chinese pharmaceutical companies will continue to strengthen, and the prospects of domestic substitution of equipment companies will continue to deepen the industry outlook will remain in a positive trend However, it is worth noting that with the normalmarket market of drug collection will be concentrated in large-scale dominant enterprises if they want to maintain the original market share or expand market share should timely adjust the sales model to change the past pharmaceutical representatives to promote marketing tactics in order to have a more advantage in the market But analysts also point out that such companies need to have an international perspective on the research and development capabilities of innovative drugs, which is not what all pharmaceutical companies can do, so that enterprises in the transition in conjunction with their own circumstances to develop an enforceable corporate strategy to survive this industry extraordinary period